Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Immunology
Saathvik R. Kannan et al.
Summary: The Omicron variant of concern (VOC) has a large number of mutations, with 46 high prevalence mutations, which may affect the binding affinities of antibodies to the S protein.
JOURNAL OF AUTOIMMUNITY
(2022)
Letter
Infectious Diseases
Lili Luo et al.
JOURNAL OF INFECTION
(2022)
Review
Virology
Dandan Tian et al.
Summary: The Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Botswana in November 2021 and has since become the dominant strain in many countries. With a high number of mutations, it presents new challenges for preventing and controlling COVID-19. This review aims to provide a scientific reference by analyzing and summarizing the biological characteristics, epidemic features, immune escape, and vaccine reactivity of the Omicron variant.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Letter
Virology
Perumal A. Desingu et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Bo Meng et al.
Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Multidisciplinary Sciences
Akatsuki Saito et al.
Summary: During the COVID-19 pandemic, the B.1.617.2/Delta variant has been found to be highly fusogenic and more pathogenic in infected hamsters compared to prototypic SARS-CoV-2. The P681R mutation in the spike protein of this variant enhances viral fusogenicity and pathogenicity.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Multidisciplinary Sciences
Katherine G. Nabel et al.
Summary: This study evaluates the impact of SARS-CoV-2 variants on neutralizing antibody activity and reveals that simultaneous antibody escape mutations make the virus more resistant to neutralization. Additionally, the study finds that the virus can acquire glycan to escape neutralization.
Article
Biochemistry & Molecular Biology
Zhen Wah Tan et al.
Summary: Recent developments in the SARS-CoV-2 pandemic highlight the importance of understanding the allostery in viral proteins for diagnostics and drug design. Allosteric drugs provide a potential solution to avoid escape mutations by inhibiting viral proteins from alternative locations.
Article
Microbiology
Ziwei Yang et al.
Summary: The variants of concern of SARS-CoV-2 have mutations that enhance transmission and reduce the effectiveness of COVID-19 vaccines and treatments. These variants have a higher propensity to bind to the human receptor and exhibit slower transitions between receptor-bound states. These findings provide insights into the adaptation strategies of SARS-CoV-2.
Article
Multidisciplinary Sciences
James W. Saville et al.
Summary: The Delta and Kappa variants of SARS-CoV-2, emerged in India in late 2020, demonstrate antibody escape and enhanced ACE2 binding, which contribute to their global dominance.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Gabriele Cerutti et al.
Summary: The Omicron variant of SARS-CoV-2, known for its high ability to evade neutralizing antibodies, has been found to have 34 mutations in the spike protein, with 15 of them occurring in the receptor-binding domain (RBD). A cryo-EM structure of the Omicron spike protein reveals that it is exclusively in the 1-RBD-up conformation, with high mobility of RBD. These mutations in the spike protein cause steric clashes and altered interactions at antibody-binding surfaces, as well as changes in local regions that interfere with antibody recognition.
Article
Immunology
Pengfei Wang et al.
Summary: The development of potent and broad-spectrum antiviral therapeutics and vaccines is crucial in dealing with highly pathogenic human coronaviruses and their evolving variants. Monoclonal antibody 2-36, isolated from COVID-19-convalescent patients, has been found to cross-neutralize SARS-CoV and other coronaviruses. The cryo-EM structure of 2-36 with SARS-CoV-2 and SARS-CoV spike reveals a conserved epitope in the receptor-binding domain (RBD). This antibody can neutralize various SARS-CoV-2 variants, as well as bat and pangolin sarbecoviruses that use human ACE2 as a receptor.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Immunology
Masaud Shah et al.
Summary: The new SARS-CoV-2 variant Omicron has enhanced transmissibility and multiple mutations that may weaken the effectiveness of therapeutic antibodies. Computational studies have shown that Omicron binds to ACE2 with a higher strength and specific mutations contribute significantly to the binding energies. These mutations also result in a drop in the electrostatic potential between RBDOmic and monoclonal antibodies, particularly etesevimab, bamlanivimab, and CT-p59. Sotrovimab, which targets a conserved epitope on the Spike protein, could be used as a cocktail therapy for Omicron-driven COVID-19.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Article
Infectious Diseases
Ivana Knezevic et al.
Summary: This article introduces the WHO Antibody Standards for SARS-CoV-2 and focuses on their application in evaluating the immune response to COVID-19 vaccines. The use of these standards facilitates comparison of assay results conducted in different countries and contributes to a better understanding of the immune response.
Letter
Medicine, General & Internal
Rebecca Rockett et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Sabrina Lusvarghi et al.
Summary: The neutralization capacity of the Omicron variant by postvaccination serum samples was found to be low, but increased significantly after a booster vaccination. Among the therapeutic antibody products tested, only a few showed high potency against Omicron. These findings highlight the importance of mRNA vaccine boosters and the need for the rapid development of antibody therapeutics to combat emerging variants.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Biology
Marco A. Diaz-Salinas et al.
Summary: This study reveals the effects of ACE2 and antibody binding on the conformational dynamics of SARS-CoV-2 spike protein. The D614G mutation and antibodies targeting diverse epitopes are found to modulate the energetics of the receptor-binding domain (RBD) position and enhance ACE2 binding. These findings offer insights into the development of therapeutic antibody cocktails.
Article
Surgery
Ilies Benotmane et al.
Summary: Preexposure prophylaxis with cilgavimab-tixagevimab does not adequately protect kidney transplant recipients against the omicron variant.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Biochemistry & Molecular Biology
Aekkachai Tuekprakhon et al.
Summary: The Omicron variant of SARS-CoV-2 has rapidly spread globally and has evolved into different sublineages, with BA.4 and BA.5 dominating in South Africa. These sublineages show reduced neutralization by vaccine and naturally immune serum, indicating the possibility of repeat Omicron infections.
Letter
Urology & Nephrology
Hannah Kaminski et al.
KIDNEY INTERNATIONAL
(2022)
Article
Infectious Diseases
Daichi Yamasoba et al.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.
Article
Biochemistry & Molecular Biology
Joseph A. Lewnard et al.
Summary: Comparison of outcomes of SARS-CoV-2 Delta and Omicron infections reveals reduced severity of Omicron infections, especially in unvaccinated individuals. There is no differential risk of severe outcomes between subvariants BA.1 and BA.2. Continual assessment of clinical outcomes associated with SARS-CoV-2 variants is crucial for medical interventions and healthcare resource management.
Article
Biochemistry & Molecular Biology
Houriiyah Tegally et al.
Summary: The genomic characterization of the SARS-CoV-2 Omicron lineages BA.4 and BA.5, responsible for the fifth wave of the COVID-19 pandemic in South Africa, reveals their continued viral diversification and sheds light on the potential mechanisms that allow these new lineages to outcompete their predecessors. These new lineages, BA.4 and BA.5, share identical spike proteins with BA.2 but have certain differences such as the presence of the 69-70 deletion, L452R, F486V, and the wild-type amino acid at Q493. They can be identified by the S-gene target failure, a proxy marker associated with the 69-70 deletion. BA.4 and BA.5 have rapidly replaced BA.2 and have become the dominant lineages in South Africa.
Article
Immunology
Zachary A. Yetmar et al.
Summary: A retrospective cohort study compared the effectiveness of bebtelovimab and sotrovimab in solid organ transplant recipients with mild-to-moderate COVID-19, showing similar rates of hospitalization and mortality between the two monoclonal antibodies.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Multidisciplinary Sciences
James Brett Case et al.
Summary: SARS-CoV-2 Omicron variant strains are less susceptible to therapeutic neutralizing antibodies. However, therapeutic antibodies S309 and AZD7442 can still reduce lung infection in a mouse model. Different antibodies have different mechanisms of protection against Omicron variants.
NATURE COMMUNICATIONS
(2022)
Review
Microbiology
Kaiming Tao et al.
Summary: The susceptibility of authorized monoclonal antibodies (MAbs) to the SARS-CoV-2 Omicron variants is not yet clear and results from studies are inconsistent. According to the findings of 51 studies, several authorized MAbs show reduced activity against the Omicron variants. Improvements in MAb susceptibility test standardization are needed to accurately assess their effectiveness against the Omicron variants.
MICROBIOLOGY SPECTRUM
(2022)
Letter
Medicine, General & Internal
Mary Y. Wu et al.
Letter
Infectious Diseases
Daniel J. Sheward et al.
LANCET INFECTIOUS DISEASES
(2022)
Article
Chemistry, Multidisciplinary
Dhiman Ray et al.
Summary: The mutations in the spike proteins of SARS-CoV-2 variants can significantly impact the neutralizing ability of monoclonal antibodies by altering their microscopic dynamics, antigen recognition thermodynamics, and motion correlation with the spike receptor binding domain. Protein-graph-connectivity networks can be used to delineate mutant-induced modifications in the information-flow along allosteric pathway throughout the antibody, leading to spatially distributed changes in collective dynamics both locally and across long-range distances.
Article
Cell Biology
Nathaniel L. Miller et al.
Summary: This study describes the mutational landscape of the Omicron variant and its impact on antibody escape and transmissibility. Using amino acid interaction networks, the researchers identify direct and indirect mutations driving increased escape breadth and depth in antibody epitopes. Additionally, they find evidence that certain Omicron RBD mutations disrupt conformational stability, potentially contributing to enhanced transmissibility.
CELL REPORTS MEDICINE
(2022)
Article
Infectious Diseases
Honorine Fenaux et al.
Summary: This case highlights the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies, especially those with persistent viral excretion, to ensure optimal management of infection and prevent transmission of selected variants.
BMC INFECTIOUS DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Deepali Gupta et al.
Summary: Since the emergence of COVID-19, the SARS-CoV-2 virus has been rapidly mutating, leading to various variants that affect transmission and virulence rates. Global infections and deaths have increased significantly, as the viral Spike protein interacts with host cells by binding to the hACE2 receptor.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Sylwester Drozdzal et al.
Summary: The COVID-19 pandemic poses a significant threat to global health with various therapeutic agents initially proclaimed to be effective, but later disproved. The Pfizer agent PAXLOVIDTM has shown promising results in reducing hospitalization time and death rates. Further development of additional treatments is needed due to the insufficiency of current recommended therapeutic options.
DRUG RESISTANCE UPDATES
(2021)
Article
Immunology
Lydia Riepler et al.
Summary: Neutralizing antibodies are crucial for protection against viruses like SARS-CoV-2. This study compared four different assays for detecting these antibodies and found that they were all robust and yielded comparable results, indicating their reliability.
Review
Multidisciplinary Sciences
Juan Li et al.
Summary: Since the emergence of COVID-19 in Wuhan in 2019, the world has faced a devastating pandemic with millions of cases and fatalities. This article provides insights into the spread and genetic variations of the SARS-CoV-2 virus, emphasizes the importance of genomic surveillance, and highlights the international transmission of major variants identified late in 2020.
Article
Multidisciplinary Sciences
Dhiman Ray et al.
Summary: Researchers are focusing on the correlation between the RBD region of the SARS-CoV-2 virus and residues distant from it to understand molecular recognition events and predict key mutations for therapeutics. Their model can identify multiple residues with long-distance coupling with the RBD opening and successfully predict some key mutations.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Biochemistry & Molecular Biology
Naveenchandra Suryadevara et al.
Summary: The study found that a subset of human monoclonal antibodies derived from convalescent SARS-CoV-2 patients possess neutralizing activity, with two antibodies capable of inhibiting infection. Mechanistic studies revealed these antibodies neutralize in part by inhibiting post-attachment steps in the infection cycle.
Review
Immunology
Dandan Tian et al.
Summary: The Delta variant of the SARS-CoV-2 virus, first reported in India in October 2020 and classified as a variant of concern by the WHO in May 2021, is highly transmissible and associated with increased hospitalization, ICU admission, and mortality rates. It has become the dominant strain in many countries globally.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Fuxing Lou et al.
Summary: This review provides the latest research progress on SARS-CoV-2 variants of interest and concern, discussing key mutation sites and their impact on virus infectivity, mortality, and immune escape. The effects of various clinical SARS-CoV-2 vaccines and convalescent sera on epidemic variants, as well as the neutralizing capability of several antibodies on these variants, are also compared and evaluated in this review.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Review
Infectious Diseases
Lucas Zhou et al.
Summary: During the global vaccination rollout, it is crucial to thoroughly understand the modes of transmission of the virus to prevent further spread; SARS-CoV-2 is primarily transmitted among humans through respiratory droplets, with environmental factors also playing a role; Wearing masks, maintaining social distancing, and washing hands are effective public health strategies in reducing the risk of exposure and transmission.
BMC INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Lin Kang et al.
Summary: The study identified a mutation in the spike protein receptor-binding domain of SARS-CoV-2, termed T372A, which enhances binding affinity to human ACE2 receptor and likely contributed to the virus's emergence from animal reservoirs. Experimental results showed that the A372 (wild-type SARS-CoV-2) replicates more efficiently in human lung cells compared to its putative ancestral variant T372.
Article
Biochemistry & Molecular Biology
Vipul Kumar et al.
Summary: The study shows that mutations in various SARS-CoV-2 variants have led to increased binding energy with hACE2, affecting the stability and interactions of spike proteins, potentially altering the impact of neutralizing antibodies on the variants. The Alpha variant exhibits stronger binding affinity, while mutations in the Kappa and Delta variants have increased intra-chain interactions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Multidisciplinary Sciences
Rita E. Chen et al.
Summary: Cell culture experiments showed reduced or abrogated neutralizing activity of monoclonal antibodies against SARS-CoV-2 variant strains, but low prophylactic doses of antibody combinations protected against infection in vivo without resistance emergence. Higher doses of several monoclonal antibody cocktails also provided protection against viruses with a B.1.351 spike gene in vivo. Many antibody products with Emergency Use Authorization should therefore retain substantial efficacy against prevailing variant strains of SARS-CoV-2.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Emanuele Andreano et al.
Summary: Research suggests that SARS-CoV-2 has the potential to generate variants resistant to neutralizing antibodies, and computational modeling predicts that these variants may prevent binding of neutralizing antibodies. Therefore, the development of vaccines and antibodies capable of controlling emerging variants is crucial.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Virology
Ivana Lazarevic et al.
Summary: Although SARS-CoV-2 evolves slowly compared to other RNA viruses, its rapid transmission during the COVID-19 pandemic has led to the emergence of numerous variants, some of which have been labeled as variants of concern. These variants may have an impact on transmission, morbidity/mortality, and evasion of neutralization by antibodies, especially monoclonal antibodies.
Article
Cell Biology
Markus Hoffmann et al.
Summary: The emergence of the B.1.617 variant in India may be responsible for the sharp increase in COVID-19 cases and deaths. B.1.617 shows increased efficiency in entering cells and evades antibody responses, contributing to its rapid spread.
Article
Immunology
Chengchao Ding et al.
Summary: Research has found that certain key mutations in the spike protein of SARS-CoV-2 may lead to the virus evading neutralization by convalescent plasmas and monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Article
Health Care Sciences & Services
Bjoern Jensen et al.
Summary: The study indicates that treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients may result in the rapid development of immune escape variants, which could have significant implications for the effectiveness of vaccination and antibody-based therapies.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Medicine, Research & Experimental
Haolin Liu et al.
Summary: The newly emerging variants of SARS-CoV-2 from South Africa and Brazil have led to a higher infection rate and reinfection of COVID-19 patients. Mutations within the receptor-binding domains of the virus increase binding affinity to the human receptor ACE2 and affect the binding of therapeutic antibodies.
Review
Immunology
Peter C. Taylor et al.
Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.
NATURE REVIEWS IMMUNOLOGY
(2021)
Review
Virology
Mohammed Uddin et al.
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Rory Henderson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Antoni G. Wrobel et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY
(2020)
Article
Multidisciplinary Sciences
Antonio E. Muruato et al.
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
M. Alejandra Tortorici et al.
Article
Multidisciplinary Sciences
Hatem A. Elshabrawy et al.
